These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 19965623)

  • 1. Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
    Pal R; Monaghan SA; Hassett AC; Mapara MY; Schafer P; Roodman GD; Ragni MV; Moscinski L; List A; Lentzsch S
    Blood; 2010 Jan; 115(3):605-14. PubMed ID: 19965623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulatory drugs act as inhibitors of DNA methyltransferases and induce PU.1 up-regulation in myeloma cells.
    Endo S; Amano M; Nishimura N; Ueno N; Ueno S; Yuki H; Fujiwara S; Wada N; Hirata S; Hata H; Mitsuya H; Okuno Y
    Biochem Biophys Res Commun; 2016 Jan; 469(2):236-42. PubMed ID: 26657848
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thalidomide derivative CC-4047 inhibits osteoclast formation by down-regulation of PU.1.
    Anderson G; Gries M; Kurihara N; Honjo T; Anderson J; Donnenberg V; Donnenberg A; Ghobrial I; Mapara MY; Stirling D; Roodman D; Lentzsch S
    Blood; 2006 Apr; 107(8):3098-105. PubMed ID: 16373662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low venous thromboembolic risk with bortezomib in multiple myeloma and potential protective effect with thalidomide/lenalidomide-based therapy: review of data from phase 3 trials and studies of novel combination regimens.
    Zangari M; Fink L; Zhan F; Tricot G
    Clin Lymphoma Myeloma Leuk; 2011 Apr; 11(2):228-36. PubMed ID: 21575928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory Drugs (IMiDs) in Multiple Myeloma.
    Raza S; Safyan RA; Lentzsch S
    Curr Cancer Drug Targets; 2017; 17(9):846-857. PubMed ID: 28201976
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of the venous thrombotic issues associated with multiple myeloma.
    Fotiou D; Gerotziafas G; Kastritis E; Dimopoulos MA; Terpos E
    Expert Rev Hematol; 2016 Jul; 9(7):695-706. PubMed ID: 27232265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IMiD compounds affect CD34
    Li S; Fu J; Wang H; Ma H; Xu X; Yang YG; Deng S; Mapara MY; Lentzsch S
    Blood Adv; 2018 Mar; 2(5):492-504. PubMed ID: 29496670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vav1 and PU.1 are recruited to the CD11b promoter in APL-derived promyelocytes: role of Vav1 in modulating PU.1-containing complexes during ATRA-induced differentiation.
    Brugnoli F; Lambertini E; Varin-Blank N; Piva R; Marchisio M; Grassilli S; Miscia S; Capitani S; Bertagnolo V
    Exp Cell Res; 2010 Jan; 316(1):38-47. PubMed ID: 19747912
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide for multiple myeloma.
    Fouquet G; Bories C; Guidez S; Renaud L; Herbaux C; Javed S; Facon T; Leleu X
    Expert Rev Hematol; 2014 Dec; 7(6):719-31. PubMed ID: 25265911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent granulocyte colony-stimulating factor for neutropenia management in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone.
    Sun HL; Atenafu EG; Yeboah E; Reece DE; Trudel S; Kukreti V; Masih-Khan E; Winter A; Chen C
    Leuk Lymphoma; 2015 Feb; 56(2):407-14. PubMed ID: 24738975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytokine-induced myeloid differentiation is dependent on activation of the MEK/ERK pathway.
    Miranda MB; Xu H; Torchia JA; Johnson DE
    Leuk Res; 2005 Nov; 29(11):1293-306. PubMed ID: 16164983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PU.1 regulates both cytokine-dependent proliferation and differentiation of granulocyte/macrophage progenitors.
    DeKoter RP; Walsh JC; Singh H
    EMBO J; 1998 Aug; 17(15):4456-68. PubMed ID: 9687512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lenalidomide - current understanding of mechanistic properties.
    Tageja N
    Anticancer Agents Med Chem; 2011 Mar; 11(3):315-26. PubMed ID: 21426296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database.
    Palmaro A; Rougé-Bugat ME; Gauthier M; Despas F; Moulis G; Lapeyre-Mestre M
    Pharmacoepidemiol Drug Saf; 2017 May; 26(5):578-586. PubMed ID: 28198064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immunomodulatory compounds in multiple myeloma.
    Saini N; Mahindra A
    Expert Opin Investig Drugs; 2013 Feb; 22(2):207-15. PubMed ID: 23265189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
    Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
    Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?
    Mateos MV; García-Sanz R; Colado E; Olazábal J; San-Miguel J
    Br J Haematol; 2008 Feb; 140(3):324-6. PubMed ID: 18067473
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pomalidomide in the treatment of relapsed and refractory multiple myeloma].
    Roziaková L; Mistrík M; Bátorová A
    Klin Onkol; 2014; 27(5):318-25. PubMed ID: 25312708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pomalidomide for multiple myeloma].
    Dougé A; Lemal R; Chaleteix C
    Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of Bcr-Abl on C/EBP transcription-factor regulation and neutrophilic differentiation are reversed by the Abl kinase inhibitor imatinib mesylate.
    Schuster C; Forster K; Dierks H; Elsasser A; Behre G; Simon N; Danhauser-Riedl S; Hallek M; Warmuth M
    Blood; 2003 Jan; 101(2):655-63. PubMed ID: 12393654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.